101 related articles for article (PubMed ID: 7578412)
1. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects.
Haubrich R; McCutchan JA; Holdredge R; Heiner L; Merritt J; Merchant B
Hum Gene Ther; 1995 Jul; 6(7):941-55. PubMed ID: 7578412
[No Abstract] [Full Text] [Related]
2. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data.
MacGregor RR; Boyer JD; Ciccarelli RB; Ginsberg RS; Weiner DB
J Infect Dis; 2000 Jan; 181(1):406. PubMed ID: 10608800
[No Abstract] [Full Text] [Related]
3. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
[TBL] [Abstract][Full Text] [Related]
4. Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics.
Ragheb JA; Bressler P; Daucher M; Chiang L; Chuah MK; VandenDriessche T; Morgan RA
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1343-53. PubMed ID: 8573391
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial to evaluate the safety and biological activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatic HIV-1 infected subjects.
Galpin JE; Casciato DA; Richards SB
Hum Gene Ther; 1994 Aug; 5(8):997-1017. PubMed ID: 7948149
[No Abstract] [Full Text] [Related]
6. Retroviral vectors for HIV immunotherapy.
Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
[No Abstract] [Full Text] [Related]
7. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.
Junker U; Böhnlein E; Veres G
Gene Ther; 1995 Nov; 2(9):639-46. PubMed ID: 8548553
[TBL] [Abstract][Full Text] [Related]
8. Transduction of CD34+ cells from the bone marrow of HIV-1-infected children: comparative marking by an RRE decoy gene and a neutral gene.
Hum Gene Ther; 2000 Jul; 11(11):1577-90. PubMed ID: 10945771
[No Abstract] [Full Text] [Related]
9. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
Liem SE; Ramezani A; Li X; Joshi S
Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins.
Morgan RA; Walker R
Hum Gene Ther; 1996 Jun; 7(10):1281-306. PubMed ID: 8793552
[No Abstract] [Full Text] [Related]
11. Regulation of HIV-1 envelope protein synthesis by Tat and Rev in 293 cells.
Natarajan V; Radjendirane V; Salzman NP
Virology; 1993 Sep; 196(1):122-9. PubMed ID: 8356789
[TBL] [Abstract][Full Text] [Related]
12. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
13. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for HIV infection.
Morgan RA
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():41-4. PubMed ID: 9020935
[TBL] [Abstract][Full Text] [Related]
15. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients.
Woffendin C; Ranga U; Yang Z; Xu L; Nabel GJ
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2889-94. PubMed ID: 8610137
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
17. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA.
Mautino MR; Morgan RA
Hum Gene Ther; 2002 Jun; 13(9):1027-37. PubMed ID: 12067436
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
Ragheb JA; Couture L; Mullen C; Ridgway A; Morgan RA
Hum Gene Ther; 1999 Jan; 10(1):103-12. PubMed ID: 10022535
[TBL] [Abstract][Full Text] [Related]
19. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
20. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals.
Ranga U; Woffendin C; Verma S; Xu L; June CH; Bishop DK; Nabel GJ
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1201-6. PubMed ID: 9448309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
